Arrival time to Pfizer’s HQ was 8am and as you can see, we have a squad of advocates with a seat at the table…more to come #stoptalkingdosomthing
Health, Hope, 𝄞 Hip-Hop Foundation’s Post
More Relevant Posts
-
The reasons WHY diversity in clinical trials is important are clear. HOW to achieve it in practice remains a challenge. This draft guidance can now be part of the toolkit to help the clinical research community stakeholders make tangible progress in this regard.
‼️ It's here! The FDA's updated draft guidance on diversity action plans for underrepresented populations in clinical trials was just released. Let's dig in! 🤓 Have you read it yet? What are your thoughts? https://lnkd.in/eXCe4q38 #HealthEquity #ClinicalTrialDiversity #InclusiveResearch #NOWINCLUDED
To view or add a comment, sign in
-
Distrust of this treatment was strong initially, but only with a small percentage of the population. Those of us familiar with that metric will remember when the so called "pro-vaxxers" would ask for peer-reviewed studies to prove it was unsafe. But there weren't any at that stage because it was all new. Now things are different. Today there are thousands of peer reviewed studies and thousands of esteemed doctors saying in various ways: this stuff is not safe / not effective. Clearly there needs to be redress here, an investigation. Not sure if WHO is up for the challenge of a transparent and comprehensive review of the global effects here.
Watch Peter McCullough, MD, MPH comment on the latest court admission by AstraZeneca. America First with Sebastian Gorka. #MFEducation
To view or add a comment, sign in
-
Join us next Wednesday for a live webinar where expert panelists will discuss improving LGBTQIA+ inclusion in clinical trials. Learn about gender-neutral protocols, inclusive trial communication, and the FDA's draft guidance on diversity plans. Don't miss out! Enroll today (with or without contact hours) > https://bit.ly/3VhX1Vn Citeline Adobe Johnson & Johnson SGM Alliance #Webinar #ContinuingEducation #ClinicalResearch #ClinicalTrials
To view or add a comment, sign in
-
Support. Don’t Punish Campaign. AHRA Announcement on the Support. Don’t Punish Campaign. Join the movement for change! Support. Don’t Punish advocates for compassionate drug policies prioritizing public health and human rights. We’re fixing the broken system and shifting the narrative. On the ! Support. Don’t Punish Global Day of Action (26th June), we unite worldwide to challenge oppressive drug control practices. Our goals: raise awareness, empower communities, and engage policymakers. Key message: Prioritize health and harm reduction in drug policy. End criminalization of people who use drugs. Advocate for balanced budgets supporting health-based approaches. Oppose the death penalty for drug offences. Reject disproportionate punishments for those in the drug trade. Stay tuned to our social media for upcoming activities. Let’s create a world where support triumphs over punishment. See the Support. Don’t Punish Campaign Statement by the Malaysian AIDS Council Building Empathy, Transforming Lives. Join us in transforming drug policies!
To view or add a comment, sign in
-
Michael Sherman and I take on the evolving state of Prescription Drug Affordability Boards (PDABs) in a new article on RApport. We’re getting the impression that we’re watching the rules being made up as they go along just as definition of "affordability" seems to fluctuate depending on who is asked. While a degree of subjectivity motivated by a desire to score easy political points in the court of popular opinion reigns over state-based PDABs, fortunately, we’re also witnessing the power of organized and impassioned patient advocacy to slow, reverse, and maybe someday reshape misinformed public policy. We're also seeing what happens when patients don't show up to fight back. In looking at the Colorado PDAB, which is both making headlines and charting the course for PDABs in other states, can already make a handful of judgements on the process, and begin to hypothesize about what might happen in other states. Importantly, we note the stark differences between how patient communities responded to the Trikafta and Enrbel reviews. Both are effective treatments in their own right, but one is a new with no alternative, while the other is 25 years old and exists in a competitive market. Does the novelty of a drug matter, and if does then to whom? Ultimately, "affordability" is a murky word, and because of that we must hope that patient groups can fend off PDABs from making state-level mistakes based on their diagnosis of the affordability problem. This is the kind of policy that generates good-looking headlines to appease frustrated voters who want to see elected officials doing something, anything, and even the wrong thing to address their anger over out-of-pocket costs. In the long run, it will probably prove embarrassing to its proponents. The question is how to mitigate its harms in the meantime. Patients and their advocates can make the difference. #healthpolicy #PDAB #patientadvocacy #drugpricing #accessandaffordability https://lnkd.in/e39-ri4N
To view or add a comment, sign in
-
Thank you Dan Schell for bringing this insightful discussion to the fore. I particularly enjoyed Jessica Jolly’s point that data should be “usable, findable, searchable, accessible and available” to the people who need it, notably data scientists, but that we’re not currently there yet. And Mohammad Hassan Khalid’s experience on managing risk around data flow and data governance and the importance of using logs to determine risk, having had the experience of catching things that, downstream, would have caused problems. Also discussed was the importance of speed, efficiency and innovation in clinical development. Of that, there was the example of using predictive modelling and adaptive clinical trial designs. It made me think of PhaseV, who have used advanced technologies and innovative statistical methods to revolutionize trial design, execution, and analysis. I’m looking forward to seeing how ICH’s M11 guideline goes on to impact our industry more broadly, promoting standardization and automation.
Did you forget about our Clinical Leader Live yesterday or miss it because you had to go to a Halloween parade/event/trunk or treat/etc.? I got you covered. Here's the entire video from our "𝗛𝗼𝘄 𝗖𝗮𝗻 𝗪𝗲 𝗜𝗺𝗽𝗿𝗼𝘃𝗲/𝗦𝗶𝗺𝗽𝗹𝗶𝗳𝘆 𝘁𝗵𝗲 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗧𝗿𝗶𝗮𝗹 𝗗𝗶𝗴𝗶𝘁𝗮𝗹 𝗗𝗮𝘁𝗮𝗳𝗹𝗼𝘄?" featuring Jessica Jolly and Mohammad Hassan Khalid of AstraZeneca. Now you owe me some of that leftover candy. 🍬 https://lnkd.in/gxNGzKbU
To view or add a comment, sign in
-
This week, I joined people from across northern NSW for day 2 of the Drug Summit in Lismore. It was great to hear the varied perspectives from community members and health professionals, united in the effort to tackle important issues around drug use and health in our region. In the future, I hope to see representation from more young people living in regional areas. Effective and compassionate drug and alcohol policy is so critical for the work we all do in this sector. Key takeaways for me include that it is well past time to take minor drug use out of the criminal space. We need more treatment options, not punishment. Law enforcement ties up resources, fails to address underlying needs, and creates stigma. Investment in proven approaches guided by lived experience, including decriminalisation, testing and safe injecting rooms, will take political courage but reap massive benefits for our community. The summit will conclude next month in Sydney. I was at the first Drug Summit in 1999 and witnessed the birth of some great reforms. There were also missed opportunities with some political leaders not ready to adopt evidence-based approaches. Hopefully with passage of time and a new generation of leaders, we will see some brave and effective reforms from this year’s event. #NSWDrugSummit2024 #RegionalNSW #PositiveSocialChange
To view or add a comment, sign in
-
Today, on #WorldDrugDay, UNODC releases of the latest #WorldDrugReport. This comprehensive report offers invaluable insights for Member States, drug policy experts, and researchers, fostering stronger cooperation at all levels. The #RightToHealth is not just a principle but a fundamental #HumanRight echoed in the 2030 Agenda for Sustainable Development. This year's #WDR features a critical chapter on Drug Use and The Right to Health: Towards an Assessment of The Framework. It underscores the essential human right to health and the importance of informed policy-making for individuals and communities impacted by drug use. We must focus on "Removing barriers to access drug-related treatment, including stigma and discrimination, and ensuring the participation of people who use drugs in decisions related to their treatment and care." Access the full report https://lnkd.in/deWaCPwc and the Special Chapter on The Right to Health in The Contemporary Issues on Drugs booklet - https://lnkd.in/eAzdhpBP #WorldDrugDay #RightToHealth #DrugPolicy #Research #SDG #WDR24
To view or add a comment, sign in
-
Selection of Drug of choice for different diseases in different organ systems.
Drug of Choice
To view or add a comment, sign in
-
All you need to know about Drug Of Choice For Diseases Of Various Systems In The Human Body🙌
Drug of Choice
To view or add a comment, sign in
330 followers
Vice President Patient Solutions & Alliances - Oncology at Pfizer
1moOya G. appreciate you! Thanks for time well spent together today. Thanks for your advocacy, your time and for sitting at the table together.